Brentuximab for Newly Diagnosed Hodgkin Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 1 - 29 |
| Updated: | 3/15/2019 |
| Start Date: | May 2015 |
| End Date: | June 2020 |
| Contact: | Jessica Hochberg, MD |
| Email: | jessica_hochberg@nymc.edu |
| Phone: | 9145942132 |
A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma
The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well
tolerated and effective in children, adolescents and young adults with all stages of newly
diagnosed Hodgkin lymphoma (HL).
tolerated and effective in children, adolescents and young adults with all stages of newly
diagnosed Hodgkin lymphoma (HL).
Inclusion Criteria:
- Normal Serum creatinine based on age or creatinine clearance >60 ml/min/1.73 m2 or an
equivalent radioisotope glomerular filtration rate (GFR) as determined by the
institutional normal range.
- Direct bilirubin < 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT
(ALT) <3 x ULN
- Shortening fraction >27% by echocardiogram, or
- Ejection fraction of >50% by radionuclide angiogram or echocardiogram.
- For patients age 1-16 years, Lansky score of ≥60.
- For patients > 16 years, Karnofsky score of ≥60.
- No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal
irradiation (<1000cGy) for superior vena cava (SVC) syndrome.
Exclusion Criteria:
- Females who are pregnant (positive HCG) or lactating.
- Karnofsky <60% or Lansky <60% if less than 16 years of age.
- Age ≤1 year or >29.99 years of age.
We found this trial at
1
site
40 Sunshine Cottage Road
Valhalla, New York 10595
Valhalla, New York 10595
(914) 594-4000
Phone: 914-594-2150
New York Medical College The College was founded in 1860 by a group of New...
Click here to add this to my saved trials
